Trametinib, an oral MEK1 and MEK2 inhibitor, has been approved by the FDA in 2014 for BRAF V600 mutated melanoma treatment in a combination with the BRAF inhibitor dabrafenib. The gene discussed is BRAF; the disease is melanoma.